TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Option Overview for Oropharyngeal Cancer
Source: Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
An optimal approach for the treatment of oropharyngeal cancer is not easily defined because no single regimen offers a distinct superior-survival advantage. The literature reports various therapeutic options but does not present any valid comparative studies of these options. Treatment considerations should account for functional and performance status, including speech and swallowing outcomes.
| Stage (TNM Definitions) | Treatment Options |
|---|---|
| Stage I and stage II oropharyngeal cancer | Radiation therapy using standard fractionation |
| Surgery | |
| Stage III and stage IV oropharyngeal cancer | Surgery followed by postoperative radiation therapy (PORT) with or without concurrent chemotherapy for patients with locally advanced disease |
| Radiation therapy using altered fractionation | |
| Concurrent chemoradiation therapy | |
| Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy | |
| Chemoradiation therapy with immunotherapy (under clinical evaluation) | |
| Treatment de-intensification using radiation dose de-escalation (under clinical evaluation) | |
| Treatment de-intensification using transoral surgery followed by radiation dose de-escalation (under clinical evaluation) | |
| Metastatic and recurrent oropharyngeal cancer | Surgical resection, if technically feasible and the tumor does not respond to radiation therapy |
| Radiation therapy, if the tumor is not completely removed by surgery and curative doses of radiation have not been given previously | |
| A second surgery, if the tumor was not completely removed initially and if technically feasible | |
| Chemotherapy, for unresectable locoregionally recurrent disease | |
| Additional radiation therapy using conventionally fractionated radiation therapy or hyperfractionated radiation therapy with concurrent chemotherapy | |
| Stereotactic body radiation therapy with concurrent cetuximab | |
| Immunotherapy | |
| Clinical trials evaluating additional radiation therapy using hyperfractionated radiation therapy with concurrent chemotherapy, targeted therapy, stereotactic body radiation therapy, or immunotherapy |
Source links and citations
- TNM Definitions
- Radiation therapy using standard fractionation
- Surgery
- Surgery followed by postoperative radiation therapy (PORT) with or without concurrent chemotherapy for patients with locally advanced disease
- Radiation therapy using altered fractionation
- Concurrent chemoradiation therapy
- Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy
- Chemoradiation therapy with immunotherapy
- Treatment de-intensification using radiation dose de-escalation
- Treatment de-intensification using transoral surgery followed by radiation dose de-escalation
- Surgical resection
- Radiation therapy
- surgery
- Chemotherapy
- radiation therapy
- Immunotherapy
- Clinical trials evaluating additional radiation therapy using hyperfractionated radiation therapy with concurrent chemotherapy, targeted therapy, stereotactic body radiation therapy, or immunotherapy
Continue within this section
Surgery and/or Radiation Therapy →Surgery Followed by Postoperative Radiation Therapy (PORT) With or Without Concurrent Chemotherapy for Patients With Locally Advanced Disease →Radiation Therapy →Concurrent Chemoradiation Therapy →Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation Therapy →Fluorouracil Dosing →
Preserved source evidence · Not medical advice